



07-15-04

IFW

Patent Docket P1857R1P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Heather Flores et al. Serial No.: 10/771,254 Filed: February 3, 2004 For: APO-2 LIGAND/TRAIL FORMULATIONS	Group Art Unit: 1645 Examiner: Not Yet Assigned Confirmation No: 2580 CUSTOMER NO: 09157 CERTIFICATE OF EXPRESS MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service Express mail service, No. EV351926233, and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 14, 2004 <i>Diane L. Marschang</i> Diane L. Marschang
-----------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] **37 CFR § 1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003 (1276 OG 55). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).


The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: July 14, 2004

By:



Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1857R1P1Serial No.
10/771,254

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Flores et al.Filing Date
03 Feb 2004Group
1645

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	5,763,223	09.06.98	Wiley et al.			
	* 2	6,030,945	29.02.00	Ashkenazi, A.			
	* 3	6,284,236	04.09.01	Wiley, et al.			
	* 4	6,541,606	01.04.03	Margolin et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	5	417,563	20.03.91	EP			
	6	870,827	14.10.98	EP			
	7	US 00/15512	14.12.00	PCT (EQUIVALENT TO WO 00/75191)			
	8	US 00/17579	04.01.01	PCT (EQUIVALENT TO WO 01/00832)			
	9	US 01/23691	07.02.02	PCT (EQUIVALENT TO WO 02/09755)			
	10	US 99/01039	22.07.99	PCT (EQUIVALENT TO WO 99/36535)			
	11	US 99/06673	26.03.99	PCT (EQUIVALENT TO WO 99/48527)			
	12	WO 01/00832	04.01.01	PCT			
	13	WO 97/01633	16.01.97	PCT			
	14	WO 97/25428	17.07.97	PCT			
	15	WO 98/18921	07.05.98	PCT			
	16	WO 98/28426	02.07.98	PCT			
	17	WO 98/32856	30.07.98	PCT			
	18	WO 98/35986	20.08.98	PCT			
	19	WO 98/41629	24.09.98	PCT			
	20	WO 98/46643	22.10.98	PCT			
	21	WO 98/46751	22.10.98	PCT			
	22	WO 98/51793	19.11.98	PCT			
	23	WO 99/02653	21.01.99	PCT			
	24	WO 99/09165	25.02.99	PCT			
	25	WO 99/11791	11.03.99	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

26	Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40." <u>Nature</u> , 357(6373):80-82 (1992)
27	Ashkenazi et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand" <u>Journal of Clinical Investigation</u> 104(2):155-162 (1999)
28	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
29	Bodmer et al., "Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 275:20632-20637 (2000)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1857R1P1	Serial No. 10/771,254
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Flores et al.	
				Filing Date 03 Feb 2004	Group 1645
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
30	Brockhaus et al., "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies." <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)				
31	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)				
32	Chicheportiche et al., "TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis." <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)				
33	Chinnaiyan et al., "Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 97:1754-1759 (2000)				
34	Darby and Creighton, "Disulfide Bonds in Protein Folding and Stability" <u>Methods in Enzymology</u> , B.A. Shirley, Totowa, NJ:Human Press Inc, Chapter 10, Vol. 40:219-252 (1995)				
35	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)				
36	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)				
37	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)				
38	Gazitt, Y., "TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells" <u>Leukemia</u> 13:1817-1824 (1999)				
39	Gliniak and Le, "Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo is Enhanced by the Chemoptherapeutic Agent CPT-11" <u>Cancer Research</u> 59:6153-6158 (1999)				
40	Goodwin et al., "Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor." <u>Mol. Cell. Bio.</u> 11:3020-3026 (1991)				
41	Griffith et al., "Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL" <u>Journal of Experimental Medicine</u> 189:1343-1353 (1999)				
42	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)				
43	Hahne et al., "APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth." <u>Journal of Experimental Medicine</u> 188(6):1185-1190 (1998)				
44	Hale et al., "Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. coli." <u>J. Cell. Biochem.</u> (abstract only, suppl. 15F; P 424) pps. 113 (1991)				
45	Hohman et al., "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNF α)" <u>Journal of Biological Chemistry</u> 264:14927-14934 (1989)				
46	Hymowitz et al., "A unique zinc-binding site revealed by the high-resolution X-ray structure of homotrimeric Apo2L/TRAIL" <u>Biochemistry</u> 39(4):633-640 (2000)				
47	Hymowitz et al., "Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5." <u>Molecular Cell</u> 4(4):563-571 (1999)				
48	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis." <u>Cell</u> 66:233-243 (1991)				
49	Jeremias et al., "TRAIL/Apo-2-ligand-induced apoptosis in human T cells" <u>European Journal of Immunology</u> 28:143-152 (1998)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1857R1P1

Serial No.

10/771,254

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Flores et al.

Filing Date

03 Feb 2004

Group

1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

50	Jo et al., "Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand" <u>Nature Medicine</u> 6(5):564-567 (2000)
51	Johnsen et al., "Regulation of Apo-2 Ligand/TRAIL Expression in NK cells-Involvement in NK Cell-Mediated Cytotoxicity" <u>Cytokine</u> 11:664-672 (1999)
52	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
53	Katsikis et al., "Interleukin-1 β Converting Enzyme-like Protease Involvement in Fas-induced and Activation-induced Peripheral Blood T Cell Apoptosis in HIV Infection. TNF-related Apoptosis-inducing Ligand Can Mediate Activation-induced T Cell Death in HIV Infection" <u>Journal of Experimental Medicine</u>
54	Keane, et al., "Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines" <u>Cancer Research</u> 59:734-741 (February 1, 1999)
55	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor." <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
56	Lawrence et al., "Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions" <u>Nature Medicine</u> 7(4):383-385 (April 2001)
57	Lewis et al., "Cloning and Expression of cDNAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demonstrate One Receptor is Species Specific." <u>PNAS USA</u> , 88:2830-2834 (1991)
58	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
59	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
60	Mallet et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes-- A Molecule Related to Nerve Growth Factor Receptor." <u>EMBO Journal</u> 9(4):1063-1068 (1990)
61	Mariani et al., "Interleukin 1 β -converting Enzyme Related Proteases/Caspases Are Involved in TRAIL-induced Apoptosis of Myeloma and Leukemia Cells" <u>Journal of Cell Biology</u> 137:221-229 (1997)
62	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
63	Marsters et al., "Identification of a Ligand for the Death-Domain-Containing Receptor Apo3." <u>Current Biology</u> , 8(9):525-528 (1998)
64	Miura et al., "Critical Contribution of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) to Apoptosis of Human CD4 T Cells in HIV-1-infected hu-PBL-NOD-SCID Mice" <u>Journal of Experimental Medicine</u> 193:651-660 (2001)
65	Mizutani et al., "Synergistic Cytotoxicity and Apoptosis by Apo-2 Ligand and Adriamycin against Bladder Cancer Cells" <u>Clin. Cancer Res.</u> 5:2605-2612 (1999).
66	Mongkolsapaya et al., "Cutting Edge: Lymphocyte Inhibitor of TRAIL (TNF-Related Apoptosis-Inducing Ligand): A New Receptor Protecting Lymphocytes From the Death Ligand TRAIL." <u>J. Immunol.</u> 160(1):3-6 (1998)
67	Moore et al., "BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator." <u>Science</u> , 285(5425):260-263 (1999)
68	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor- κ B, and c-Jun NH ₂ -Terminal Kinase" <u>J. Bio. Chem.</u> 274:15978-15981 (1999)
69	Nagata, S., "Steering anti-cancer drugs away from the TRAIL" <u>Nature Medicine</u> 6(5):502-503 (May 2000)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1857R1P1	Serial No. 10/771,254
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Flores et al.	
				Filing Date 03 Feb 2004	Group 1645
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
70	Nophar et al., "Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor." <u>EMBO Journal</u> . 9:3269-3278 (1990)				
71	Pan et al., "An Antagonist Decoy Receptor and a Death-Domain Containing Receptor for TRAIL." <u>Science</u> . 277:815-818 (Aug 1997)				
72	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." <u>Science</u> . 276:111-113 (Apr 4, 1997)				
73	Pan et al., "TRUNDD, A New Member of the TRAIL Receptor Family That Antagonizes TRAIL Signalling." <u>FEBS Letters</u> . 424(1-2):41-45 (1998)				
74	Pitti et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer." <u>Nature</u> . 396(6712):699-703 (1998)				
75	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)				
76	Qin et al., "Avoiding premature apoptosis of normal epidermal cells" <u>Nature Medicine</u> 7(4):385-386 (April 2001)				
77	Radeke et al., "Gene Transfer and Molecular Cloning of the Rat Nerve Growth Factor Receptor." <u>Nature</u> . 325:593-597 (1987)				
78	Rieger et al., "APO2 ligand: a novel lethal weapon against malignant glioma?" <u>FEBS Letters</u> 427:124-128 (1998)				
79	Roth et al., "Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity" <u>Biochem. Biophys. Res. Comm</u> 265:479-483 (1999)				
80	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)				
81	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruct. Mediated by Cytotoxic T-cell Lines, Lymphotoxin-Secreting Helper T-cell Clones, and Cell-Free Lymphotoxin-Containing Supernatant." <u>PNAS USA</u> . 83:1881-1885 (1986)				
82	Schneider et al., "BAFF, A Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" <u>Journal of Experimental Medicine</u> 189:1747-1756 (1999)				
83	Schneider et al., "Characterization of Two Receptors for TRAIL." <u>FEBS Letters</u> . 416:329-334 (1997)				
84	Screaton et al., "TRICK2, A New Alternatively Spliced Receptor that Transduces the Cytotoxic Signal From TRAIL." <u>Current Biology</u> . 7:693-696 (1997)				
85	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)				
86	Shu et al., "TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens." <u>J. Leukocyte Biol</u> . 65:680-683 (1999)				
87	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)				
88	Smith et al., "T2 Open Reading Frame From the Shope Fibroma Virus Encodes a Soluble Form of the TNF Receptor." <u>Biochem. & Biophys. Res. Comm</u> . 176:335-342 (1991)				
89	Song et al., "Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression" <u>Journal of Experimental Medicine</u> 191(7):1095-1103 (2000)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1857R1P1

Serial No.

10/771,254

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Flores et al.

Filing Date

03 Feb 2004

Group

1645

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	90	Stamenkovic et al., "A B-Lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomas." <u>EMBO Journal.</u> 8(5):1403-1410 (1989)
*	91	Thomas and Hersey, "TNF-Related Apoptosis-Inducing Ligand (TRAIL) Induces Apoptosis in Fas Ligand-Resistant Melanoma Cells and Mediates CD4 T Cell Killing of Target Cells" <u>J. Immunol.</u> 161:2195-2200 (1998)
	92	Upton et al., "Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence." <u>Virology.</u> 184:370-382 (1991)
	93	Upton et al., "Tumorigenic Poxviruses: Genomic Organization and DNA Sequence of the Telomeric Region of the Shope Fibroma Virus Genome." <u>Virology.</u> 160:20-30 (1987)
	94	Walczak et al., "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL." <u>EMBO Journal.</u> 16(17):5386-5397 (1997)
	95	Walczak et al., "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo" <u>Nature Med.</u> 5:157-163 (1999)
	96	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
	97	Wu et al., "KILLER/DR5 is a DNA Damage-Inducible p53-Regulated Death Receptor Gene." <u>Nature Genetics.</u> 17:141-143 (1997)
	98	Yu et al., "Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Androgen-independent Prostate Cancer Cells" <u>Cancer Research</u> 60:2384-2389 (2000)
.		
.		

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.